Coronavirus... Moscow Begins Vaccinating against Citizens over 60

Today, Monday, authorities in the Russian capital, Moscow, began remotely registering citizens over the age of 60 in preparation for vaccination against the Coronavirus.

According to the Mayor of Moscow, Sergey Sobyanin, the elderly are the most vulnerable group when infected with the Coronavirus.

He announced, that after the health authorities approved the possibility of vaccination against "COVID-19" with the "Sputnik V" vaccine for citizens over the age of 60 years, the capital authorities, as of December 28, will open registration for their vaccination.

He expressed his hope that in the coming weeks, vaccination will be available to all residents of the capital.

And the capital's authorities intend to vaccinate some 6-7 million people during the coming period.

The vaccination campaign against the Coronavirus began in Moscow on December 5, and about 15,000 people have been vaccinated so far.

On  Saturday, the Russian Minister of Health, Mikhail Murashko, announced that the "Sputnik V" vaccine has been approved against the Coronavirus, to vaccinate people over the age of 60 years.

The minister confirmed that the "Sputnik V" vaccine has proven safe for people over the age of 60 years.

He said that the Ministry of Health has approved amendments to the medical use instructions.

Sputnik's vaccine has been approved for people over the age of 18 years,"

The Russian "Gamalia" Center for Microbiology announced the results of tests for its "Sputnik V" vaccine against the emerging coronavirus on elderly volunteers.

The head of the center, Alexander Ginsburg, confirmed during a press briefing held last Thursday that the tests in which many residents of the capital, Moscow, over the age of 60, participated several days ago, and their scientific results were extracted today and delivered to the Ministry of Health.

Ginsburg said that the test results are very good and do not lag behind the results of the tests conducted on volunteers of other age groups during the three stages of the clinical vaccine tests.